|Articles|September 2, 2020

AstraZeneca COVID-19 vaccine to US Phase 3 trial

According a press release and a recent article from Drug Topics, AstraZeneca’s investigational vaccine candidate AZD12222 expanded into a phase 3 clinical trial.

The trial is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).

Up to 30,000 adults aged 18 years or older will be enrolled to assess the safety and immunogenicity of AZD1222, which was co-invented by the University of Oxford and Vaccitech.

For more information, read the full article from Drug Topics.

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

AstraZeneca COVID-19 vaccine to US Phase 3 trial

Related Content

Kate McLean, MD, MPH, explains microbial subtypes within bacterial vaginosis

Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support

Subfecundity, not IVF, linked to elevated neurodevelopmental risk in offspring

Third trimester cervical length could help identify women at risk of spontaneous preterm birth

Saffron extract linked to mood and sleep gains in menopausal women

Trending on Contemporary OB/GYN

Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support

Subfecundity, not IVF, linked to elevated neurodevelopmental risk in offspring

Kate McLean, MD, MPH, explains microbial subtypes within bacterial vaginosis

Psychological and urogenital menopause symptoms similarly burdensome regardless of age at menopause onset

Third trimester cervical length could help identify women at risk of spontaneous preterm birth